Connor, Clark & Lunn Investment Management (CC&L)
OREX

Connor, Clark & Lunn Investment Management (CC&L)’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,870
Closed -$32K – 981
2015
Q4 		$32K Buy
+1,870
New +$44.6K ﹤0.01% 798

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s OREX Position: Q1 2016 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2016, closing a stake of 1,870 shares — an estimated $32K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in OREX in Q4 2015 and held it in 1 quarter. The position peaked at $32K in Q4 2015. 104 funds tracked by Wall St. Rank hold OREX as of Q1 2016.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 1,870 Orexigen Therapeutics, Inc. shares in Q1 2016, an estimated $32K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Orexigen Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Orexigen Therapeutics, Inc. position peaked at $32K in Q4 2015.
  • 104 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2016.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2016, filed 13 May 2016.